Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 113608 in Healthy Male Asian and Caucasian Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups)
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2017
Price : $35 *
At a glance
- Drugs BI 113608 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 19 May 2014 Trial status changed to completed as reported by ClinicalTrials.gov.
- 19 Aug 2013 New trial record
- 01 Aug 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.